Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Transfus Apher Sci ; 63(1): 103853, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38049358

ABSTRACT

Apheresis is a modern medical approach in which plasma or cellular components are separated from the whole blood. Apheresis can be either diagnostic or therapeutic. Diagnostic apheresis is typically applied in hematology and cancer research. Therapeutic Apheresis (TA) includes a broad spectrum of extracorporeal treatments applied in various medical specialties, including Intensive Care Unit (ICU). Considering the complexity of the pathophysiologic characteristics of various clinical entities and in particular sepsis, apheresis methods are becoming increasingly applicable. Therapeutic Plasma Exchange (TPE) is the most common used method in ICU. It is considered as first line therapy for Thrombotic Thrombocytopenic Purpura (TTP) and Guillain Barre Syndrome, while the current data for sepsis are scarce. Over the last decades, technologic evolution has led to increasing application of new and more selective methods based on adsorptive techniques. In this review we will describe the current data of characteristics of different techniques, safety and clinical impact of apheresis methods used in ICUs.


Subject(s)
Blood Component Removal , Purpura, Thrombotic Thrombocytopenic , Sepsis , Humans , Blood Component Removal/methods , Plasma Exchange/methods , Plasmapheresis , Purpura, Thrombotic Thrombocytopenic/therapy , Intensive Care Units , Sepsis/therapy
2.
Transfus Apher Sci ; 61(6): 103593, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36335074

ABSTRACT

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first known case was identified in Wuhan, China, in December 2019. The disease has since spread worldwide, and on March 2020 the World Health Organization (WHO) declared it as pandemic, causing a public health crisis. Symptoms of COVID-19 are variable, ranging from mild symptoms like fever, cough, and fatigue to severe illness. Elderly patients and those with comorbidities like cardiovascular disease, diabetes, chronic respiratory disease, or cancer are more likely to develop severe forms of the disease. Asymptomatic infections have been well documented. Accumulating evidence suggests that the severity of COVID-19 is due to high levels of circulating inflammatory mediators including cytokines and chemokines leading to cytokine storm syndrome (CSS). Patients are admitted in ICU with severe respiratory failure, but can also develop acute renal failure and multi organ failure. Advances in science and technology have permitted the development of more sophisticated therapies such as extracorporeal organ support (ECOS) therapies that includes renal replacement therapies (RRTs), venoarterial (VA) or veno-venous (VV) extracorporeal membrane Oxygenation (ECMO), extracorporeal CO2 removal (ECCO2R), liver support systems, hemoperfusion, and various blood purification devices, for the treatment of ARDS and septic shock.


Subject(s)
Blood Component Removal , COVID-19 , Humans , Aged , COVID-19/therapy , SARS-CoV-2 , Pandemics , Intensive Care Units
3.
Immunol Lett ; 159(1-2): 23-9, 2014.
Article in English | MEDLINE | ID: mdl-24440200

ABSTRACT

Although several components of the microbial wall of gram-positive bacteria and fungi possess immunostimulatory properties, their pathogenetic role remains incompletely evaluated. The purpose of this study was to assess the basic immune status of patients susceptible to infections and their capability for cytokine production after stimulation with wall components of gram-positive bacteria and fungi. We measured serum cytokine levels as well as cytokine production after ex vivo lipoteichoic acid (LTA) and mannan stimulation of whole blood. The blood was taken from 10 healthy volunteers, 10 patients with end-stage renal disease (ESRD), 10 patients with diabetes mellitus (DM), and 10 patients on their 2nd day of stay in the Intensive Care Unit (ICU), who suffered from non septic systemic inflammatory response syndrome (SIRS) and had an APACHE II score ≥25. We used 1 µg/ml LTA and 100 µg/ml mannan for an incubation period of 8 h to stimulate 100 µl aliquots of whole blood. All patient groups had higher baseline values of TNF-α, IL-6, IL-1ß, and IL-10 compared to the control group, but only for ICU patients the difference was statistically significant. The ratio IL-10/IL-6 was found 0.33, 0.22, and 0.96 in healthy persons, ESRD, and DM patients respectively, and 1.32 in ICU patients. In all examined groups, the levels of cytokines significantly increased after stimulation by LTA and mannan, although in severely ill patients this change was considerably smaller, possibly reflecting a state of monocytes' depression and relative hyporesponsiveness. No significant differences between the LTA and the mannan stimulation were observed.


Subject(s)
Blood Cells/drug effects , Diabetes Mellitus, Type 2/immunology , Kidney Failure, Chronic/immunology , Lipopolysaccharides/pharmacology , Mannans/pharmacology , Systemic Inflammatory Response Syndrome/immunology , Teichoic Acids/pharmacology , Adult , Aged , Blood Cells/immunology , Blood Cells/pathology , Cell Wall/chemistry , Cells, Cultured , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/pathology , Female , Fungi/chemistry , Gram-Positive Bacteria/chemistry , Humans , Intensive Care Units , Interleukin-10/biosynthesis , Interleukin-6/biosynthesis , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/pathology , Lipopolysaccharides/isolation & purification , Male , Mannans/isolation & purification , Middle Aged , Systemic Inflammatory Response Syndrome/diagnosis , Systemic Inflammatory Response Syndrome/pathology , Teichoic Acids/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL
...